FDA approves first oral formulation of Miconazole

The FDA has approved Strativa Pharmaceuticals' Oravig (miconazole) buccal tablets for the treatment of oropharyngeal candidiasis (OPC), more commonly known as “thrush.” Oravig, which adheres to the gum, delivers miconazole antifungal medication directly at the local site of infection throughout the day with minimal systemic absorption. Says John A. MacPhee, Strativa President, "Oravig offers patients suffering from thrush a proven effective treatment in a discreet and convenient once-daily formulation." OPC is an oral fungal infection most common in individuals with weakened immune systems--particularly those with HIV/AIDS and those undergoing certain cancer treatments.

- here's the Strativa release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.